Stockreport

TLC Announces Initiation of Phase III Pivotal Clinical Trial of TLC599 for the Treatment of Osteoarthritis Knee Pain

Taiwan Liposome Company, Ltd. - American Depositary Shares  (TLC) 
PDF - Phase II results showed statistically significant pain relief through 24 weeks- Phase III to evaluate efficacy of single and repeated doses up to 52 weeks SOUTH SAN [Read more]